Last reviewed · How we verify
Transdermal Nicoderm patch
Nicotine delivered transdermally binds to nicotinic acetylcholine receptors in the brain, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation.
Nicotine delivered transdermally binds to nicotinic acetylcholine receptors in the brain, providing nicotine replacement to reduce cravings and withdrawal symptoms during smoking cessation. Used for Smoking cessation as an aid to quit smoking.
At a glance
| Generic name | Transdermal Nicoderm patch |
|---|---|
| Also known as | Habitrol |
| Sponsor | Ottawa Heart Institute Research Corporation |
| Drug class | Nicotine replacement therapy |
| Target | Nicotinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Smoking Cessation / Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
Nicoderm patches deliver nicotine across the skin at a controlled rate, maintaining steady-state plasma nicotine levels. By activating nicotinic acetylcholine receptors, particularly in the mesolimbic dopamine system, nicotine replacement reduces the withdrawal symptoms and cravings associated with smoking cessation, making it easier for patients to quit smoking.
Approved indications
- Smoking cessation as an aid to quit smoking
Common side effects
- Skin irritation at patch application site
- Headache
- Nausea
- Dizziness
- Sleep disturbances
- Vivid dreams
Key clinical trials
- iCanQuit Smoking Cessation Among Hispanic Adults (PHASE3)
- Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment (PHASE4)
- STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking (NA)
- Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings (NA)
- Effectiveness of an Integrated Treatment to Address Smoking Cessation and Anxiety/ Depression in People Living With HIV (NA)
- Varenicline and Combined NRT for Smoking Cessation (PHASE4)
- Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension (PHASE2)
- Depressed Mood Improvement Through Nicotine Dosing 3 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transdermal Nicoderm patch CI brief — competitive landscape report
- Transdermal Nicoderm patch updates RSS · CI watch RSS
- Ottawa Heart Institute Research Corporation portfolio CI